title: Posttransplantation lymphoproliferative disorder: changing manifestations of disease in a renal transplant population.
abstract: OBJECTIVE
  To review the changing manifestations of PTLD in patients with renal transplants.
  
  
  METHODS
  Review of 1954 records of the renal transplantation clinic from 1971 to 1993 produced 17 patients with the diagnosis of PTLD.
  
  
  RESULTS
  With changes in immunosuppression, the sites of involvement of PTLD have changed. Central nervous system involvement was the predominant site of disease prior to the use of cyclosporine. With the institution of cyclosporine, thoracic, and abdominal presentations became more common. PTLD isolated to the renal transplant is a new manifestation of disease that may be a result of immunosuppression with OKT3. Monomorphous PTLD was associated with a 78% PTLD related mortality. Polymorphous PTLD had a 0% PTLD related mortality. In patients with cross-sectional imaging abnormalities, PTLD presented as solitary or multiple masses in 78%. This is the finding most suggestive of PTLD in a transplant population.
  
  
  CONCLUSIONS
  Posttransplantation lymphoproliferative disorder is a heterogeneous grouping of lymphoid proliferation with variable clinical and radiographic manifestations. An understanding of the range of manifestations may lead to improved diagnosis of this unusual disorder.
authors.affiliation: Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia 19104, USA.
authors.forename: W T
authors.initials: WT
authors.lastname: Miller
authors.forename: S G
authors.initials: SG
authors.lastname: Siegel
authors.forename: K T
authors.initials: KT
authors.lastname: Montone
mesh_terms: D000005:Abdomen / Q000473:pathology; D000293:Adolescent; D000328:Adult; D001927:Brain Diseases / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000209:etiology; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D007674:Kidney Diseases / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000209:etiology; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000000981:diagnostic imaging / Q000473:pathology; D008223:Lymphoma / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000209:etiology; D008232:Lymphoproliferative Disorders / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000209:etiology* / Q000473:pathology; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000009:adverse effects / Q000627:therapeutic use; D011860:Radiography, Abdominal; D012189:Retrospective Studies; D015996:Survival Rate; D013896:Thoracic Diseases / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000209:etiology; D014057:Tomography, X-Ray Computed
chemical_list: D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016572:Cyclosporine